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1. Introduction 
Ovarian cancer is among the most deadly types of cancers among women, with about 21,990 
new cases diagnosed every year in the United States (American Cancer Society, 2011). About 
15,460 of these women will die from ovarian cancer. If diagnosed while the cancer is still 
localized, survival rates of at least 5 years are likely. Unfortunately, less than 20% of cases are 
found at an early stage due to the absence of reproducible and definitive diagnostic tools. 
Because ovarian cancers occur deep in the pelvis, there are often few symptoms until the 
cancer is at an advanced stage. Furthermore, many of the symptoms of ovarian cancer (such as 
back pain, fatigue, and abdominal bloat) are common and difficult to distinguish from those 
not caused by cancer. Because of this lack of symptom specificity, most ovarian cancers are 
substantially advanced at the time of diagnosis. Staging of the cancer is critically important in 
order to determine the most effective treatment modality. Currently there are no routine 
clinical diagnostic assays using urinalysis or seranalysis for early screening or staging of 
ovarian cancer. However, there are several research studies (Bignotti et al., 2007; and Liotta et 
al., 2005) that identify potential biomarker indicators that can be used for this purpose.  
When a woman is suspected of having ovarian cancer, medical diagnostics typically include 
an ultrasound of the abdomen and pelvis as well as a blood test that includes measurement 
of the CA-125 protein levels (American Cancer Society, 2011). CA 125 is a protein biomarker 
found in greater concentration in tumor cells than in other cells of the body. However, since 
CA-125 levels can be elevated due to other benign causes, it is primarily used to monitor 
women with a known cancer of the ovary to determine treatment efficacy. Measurement of 
CA-125 levels is not accepted as a sufficient test for an early screening indicator in ovarian 
cancer. Thus, improved methods are needed to provide a specific and early screen for this 
deadly disease.  
                                                 
Based on "Optical nanotechnology enables rapid label-free diagnostics for cancer biomarker 
screening,” by D. Wawro, S. Zimmerman, R. Magnusson and P. Koulen which appeared in 
Proceedings of SPIE 8090, 80900S (2011). * 
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In this work, we describe a high-accuracy, label-free biosensor system that can provide 
effective detection of an array of biomarker proteins in serum to accurately diagnose and 
stage ovarian cancer. While there are currently no established clinical diagnostic assays 
using urinalysis or seranalysis, experimentally and clinically identified targets (Bignotti et 
al., 2007; and Liotta et al., 2005) can be categorized into two groups: group 1 consists of 
biomarker proteins that are up-regulated twofold or higher in metastatic over primary 
ovarian serous papillary carcinoma (such as Fibronectin), and group 2 consists of biomarker 
proteins that are up-regulated twofold or higher in primary over metastatic ovarian serous 
papillary carcinoma (such as Apolipoprotein A-1). This differentiation yields accurate 
diagnosis of the disease and staging information that can be used to monitor pre-
symptomatic aspects of the disease, disease progression, and the efficacy of therapies.  
Conventional blood diagnostic testing methods such as immunoassay approaches require 
time-intensive processing and washing steps, and they are not easily integrated in a clinical 
setting. To address these needs, we utilize a real-time photonic biosensor technology that 
provides rapid results with minimal processing steps and the capability to test for an array 
of biomarkers in a single sample.  
2. Label-free diagnostic approach 
The diagnostic screening system that is central to this work applies an optical approach 
based on the guided-mode resonance (GMR) effect that occurs in subwavelength dielectric 
waveguide gratings. As shown in Fig. 1, when these diffractive elements are illuminated 
with a broadband light source, a specific wavelength of light is reflected (or transmitted) at a 
specific angle. The binding interaction between an immobilized receptor and its analyte can 
be monitored in real time without the use of reporter labels (such as fluorescent or 
radioactive tags) by following the corresponding resonance wavelength shift with an optical 
 
 
 
 
Fig. 1. (a) Schematic of a label-free GMR sensor system (single channel illustrated) operating 
in reflection mode. The collimated beam from a broadband source is incident on the sensor 
at normal incidence. The reflected spectral response is monitored in real time with an optical 
spectrum analyzer. (b) As binding events occur at the sensor surface, resonance peak 
changes (only one polarization depicted in plot) can be tracked as a function of the 
wavelength. 
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spectrum analyzer. Test time is limited solely by the chemical binding dynamics between 
the receptor and its target. Specificity is imparted on the sensor surface by covalently 
attaching a selective layer (such as antibodies). It is multifunctional as only the sensitizing 
surface layer needs to be chemically altered to detect different targets. Repeatable 
fabrication processes are in place to produce the resonant grating sensor element in low-cost 
polymer and other dielectric materials.  
Since the resonance layer is polarization-sensitive, separate resonance peaks occur for 
incident TE (electric vector normal to the plane of incidence) and TM (magnetic vector 
normal to the plane of incidence) polarization states. This dual-peak feature provides cross-
referenced data useful for increasing detection accuracy. These distinct resonant modes 
interact differently with the surrounding media, enabling the polarization-based 
differentiation. This sensor technology is broadly applicable to medical diagnostics, drug 
discovery and development, industrial process control, and environmental monitoring. 
2.1 Guided-mode resonance technology overview 
The coupling of a freely propagating electromagnetic wave to a state of confinement at a 
periodic surface is presently the subject of considerable research activity. Periodic structures 
with subwavelength features provide effective means of achieving such coupling. The 
resulting strong localization of energy at a dielectric (or metallic) layer is of interest for 
numerous photonic applications including biosensors, light sources, nonlinear frequency 
converters, and particle traps. Magnusson et al. disclosed GMR filters that were tunable on 
variation in resonance structure parameters (Magnusson & Wang, 1992). Wawro et al. 
presented GMR biosensor embodiments as well as system architectures (Wawro et al., 2000). 
Thus, spectral or angular variations induced via layer thickness change or on change in 
refractive index in surrounding media or in device layers can be used to sense these changes 
(Magnusson et al., 2011; Wawro et al., 2006; 2010). Additional aspects of GMR sensors in 
various applications have been discussed in the literature (Cunningham et al., 2002; Kikuta 
et al., 2001).  
Thin-film structures containing waveguide layers and periodic elements, under the 
correct conditions, exhibit the GMR effect. Most commonly, GMR biosensors are designed 
to operate in reflection. In this configuration, an incident wave is phase-matched, by the 
periodic element, to a leaky waveguide mode. It is reradiated in the specular-reflection 
direction as it propagates along the waveguide and constructively interferes with the 
directly reflected wave. Conversely and equivalently, the phase of the reradiated leaky 
mode in the forward, directly transmitted wave direction is  radians out of phase with 
the direct unguided transmitted wave, thereby extinguishing the transmitted light 
(Rosenblatt, 1997). This picture of the resonance effect pertains to a reflection, or 
bandstop, filter. Other operation configurations are possible, such as in transmission 
mode, or as a bandpass filter.  
Figure 2 shows the measured and calculated spectral reflectance of a dielectric GMR device 
(Priambodo et al., 2003). It acts as a bandstop filter with the spectrum of interest reflected in 
a narrow band with relatively low sidebands. Although the theoretical calculation predicts 
100% peak efficiency for a plane wave incidence, it is diminished in practice by various 
factors such as material and scattering losses, incident beam divergence, and the lateral 
device size; here, the experimental peak is 90%.  
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These resonant structures, tunable on change of refractive index and/or thickness, have 
clear applications for biosensors. The buildup of the attaching biolayer can be monitored in 
real time, without use of chemical tags, by following the corresponding resonance shift.  
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Fig. 2. Comparison between experiment and theory for a dielectric resonance element. The 
parameters used for the theoretical curve fit are close to the nominal values; they are nC=1.0, 
nH=1.454 (SiO2), n2=1.975 (HfO2), ns=1.454, d1=135 nm, f=0.58, d2=208 nm, =446 nm, 
normal incidence. Rigorous coupled-wave analysis (RCWA) is used for the computations 
(Gaylord & Moharam, 1985).  
2.2 Biosensor operation 
In addition to the reflection/transmission properties of propagating electromagnetic waves, 
the near-field properties of resonant periodic lattices, including localization and field-
strength enhancement, are of interest in sensor applications. The near-field patterns 
associated with a typical filter, similar to that in Fig. 2 in structure, are shown in Figs. 3 and 
4 with a normally incident TE-polarized wave. Numerical results are obtained with rigorous 
coupled-wave analysis (RCWA) (Gaylord & Moharam, 1985) to provide quantitative 
information on relative field strengths and spatial extents associated with the near fields. As 
shown in Fig. 3, the S0 wave (S0 denotes the electric field of the zero order) propagates with 
reflected-wave amplitude close to unity, producing the standing-wave pattern shown by 
interference with the unit-amplitude input wave used in our model. Thus, at resonance, 
most of the energy is reflected back. The evanescent, first-order diffracted waves S1 and S-1 
constitute the counter-propagating leaky modes. We see that the maximum field value is 
located in the HfO2 layer with the evanescent tails gradually penetrating into the substrate 
and cover. Figure 4 shows the standing wave pattern formed by the counter-propagating S-1 
and S+1 waves at a certain instant of time; the field scale is color coded as shown. Since the 
S1 space harmonics correspond to localized waves, they can be very strong at resonance; 
here, the field enhancement is ~x10 as seen in Fig. 3. Depending on the level of grating 
modulation (= nH2 – nL2), the field amplitude can range from ~x10-x1000 in the layer 
relative to the input wave amplitude that represents a large increase in local intensity I~S2. 
The maximum amplitude of S1 is approximately inversely proportional to the modulation 
strength. In general, small modulation implies narrow linewidth  and a large resonator Q 
factor Q= 
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Fig. 3. Profile of the leaky mode at resonance for a typical GMR sensor device. The 
amplitude is normalized to the incident-wave amplitude. 
The structure of the local fields associated with the resonant leaky modes is key to sensor 
applications. The leaky mode is a surface state that propagates along the surface, providing 
maximal interaction with any attached molecular or chemical layer. In the technology 
discussed herein, the sensing field (a resonant leaky mode) is maximized in the grating layer 
with an evanescent tail penetrating into the cover region (shown in Figs. 3 and 4).  
 
 
Fig. 4. Snapshot of the standing-wave pattern associated with the leaky mode in Fig. 3. The 
size of the region is 22. Results are obtained with rigorous coupled wave analysis. 
2.3 Sensor element fabrication 
The GMR biosensor devices used in this work are based upon a single-layer waveguide 
grating design. We fabricated these with low-cost submicron molding methods in our labs, 
and they can be purchased from numerous commercial sources. We utilize polymers that 
are imprinted with submicron grating patterns and coated with a high-index dielectric 
material (such as TiO2 or HfO2) to realize resonant sensors. Figure 5 shows an example of a 
GMR sensor.  
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                                        (a)                                                    (b) 
Fig. 5. Submicron resonant grating. (a) Atomic force microscope (AFM) picture of a ~520-nm 
period grating contact printed in an optical polymer. (b) A picture of a submicron molded 
grating. The grating is coated with a thin high-index layer (TiO2 or HfO2) to realize a GMR 
sensor element. 
2.4 Competing approaches 
Numerous optical sensors for bio- and chemical detection have been developed 
commercially and in research literature. Key label-free technologies include the surface-
plasmon resonance sensor (Homola, 2003; Raether, 1988), MEMS-based sensors, nano-
sensors (rods and particles), resonant mirror, Bragg grating sensors, waveguide sensors, 
waveguide interferometric sensors, ellipsometry, and grating coupled sensors 
(Cunningham, 1998; Cooper, 2006). Other methods include immunomagnetic separation, 
polymerase chain reaction, and standard immunoassay approaches that incorporate 
fluorescent, absorptive, radioactive, and luminescence labels. The GMR sensor approach has 
advantages and distinctions relative to these technologies, including features such as 
polarization diversity and low-power, portable system formats.  
In our opinion, although dramatically different in concept and function, the surface-
plasmon resonance (SPR) sensor (Homola, 2003; Raether, 1988) comes closest in features and 
operation to the GMR sensor discussed here. The term surface plasmon (SP) refers to an 
electromagnetic field charge-density oscillation that can occur at the interface between a 
conductor and a dielectric (for example, gold/glass interface). An SP mode can be 
resonantly excited by parallel-polarized (TM, electric vector in the plane of the page) 
incident light but not with TE polarized light. Phase matching occurs by employing a 
metallized diffraction grating, or by using total internal reflection from a high-index 
material, such as in prism coupling or an evanescent field from a guided wave. When an 
SPR surface wave is excited, an absorption minimum occurs in a specific wavelength band. 
Since only a single polarization (TM) can physically be used for detection, refractive index 
and thickness attachments cannot simultaneously be resolved in one measurement. This is 
particularly important in chemical sensor applications where binding kinetics includes 
conformational and density changes at the sensor surface.  
Standard label-based immunoassay tests involve extensive and complicated incubation and 
washing steps. In this approach, results are not obtained until 4-24 hours after starting the 
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test. By using GMR sensor technology, real-time results can be obtained with no required 
washing steps. Results are limited only by the binding dynamics of the ligand-receptor 
interactions (typically less than 30 minutes). This greatly simplifies medical diagnostic 
testing approaches, and it will enable doctor offices and hospitals to perform routine 
screening on a much larger scale with dramatically less labor.  
3. Experiments 
Numerous characterization experiments have been performed for a variety of biological and 
chemical materials utilizing GMR sensors and the Vides bioassay spectroscopic reader 
system developed by Resonant Sensors Incorporated (shown in Fig. 6). In this work, we 
evaluate this label-free screening tool for the detection of biomarker proteins fibronectin and 
apolipoprotein A-1 (ApoA-1), which are relevant in ovarian cancer. The sensor plate (shown 
in Fig. 6(b)) is incorporated in the bottom of a bottomless microarray plate. Each well is 
sensitized to detect a target analyte by immobilizing a selective layer (such as highly specific 
antibodies). The spectroscopic sensor system approach (as shown in Fig. 1) tracks the GMR 
resonance peak wavelength changes as a function of time during a biochemical interaction. 
The relative peak shift is correlated to a concentration for a particular analyte in a serum or 
cell culture sample. We use an in vitro cell model for ovarian cancer to provide the relevant 
expressed biomarker proteins under test. Additionally, we investigate the impact of 
nonspecific binding and cross reactivity in complex samples such as human serum and cell 
media. 
 
    
Fig. 6. (a) A benchtop spectroscopic detection system utilizing GMR biosensor technology 
developed by Resonant Sensors Incorporated (RSI). In this arrangement, the spectral 
reflectance is monitored with an optical spectrum analyzer, and the peak wavelength is 
tracked as a function of time during a biochemical event. (b) This bioassay reader utilizes 96-
well (shown here) or 384-well (not shown) sensor array plates. 
3.1 In vitro cell model 
Human cell lines are used for the detection of relevant biomarker proteins and feasibility of 
sensor operation in complex samples. In order to combine the highest possible clinical 
relevance for the most financially viable research plan, the in vitro models for ovarian cancer 
(a) 
(b) 
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are chosen based on human cell lines that had been derived directly from patients with 
ovarian cancer and are not from other types of cancer with ovarian side effects/metastases. 
Additionally, the in vitro models are established (used by ovarian cancer researchers in peer-
reviewed publications) and reproducible (available through ATCC). 
Two different cell lines are used to provide samples for the detection of ovarian cancer 
biomarker proteins as shown in Table 1. The cell culture supernatant, which contains the 
expressed biomarker proteins, is measured to determine the concentrations of fibronectin 
and apolipoprotein A-1 (detailed in next section). We culture both cell lines as follows:  
3.1.1 Cell culture growth 
Cells are thawed and transferred to a 15 ml conical tube. Cells are spun at 200 x g for 1 
minute. The supernatant is removed and replaced with 1 ml of Complete Medium (MCDB 
105 and Medium 199, with fetal bovine serum). A cell count is done on the Nexcelom T4 
Cellometer (Nexcelom Bioscience LLC, Lawrence, MA). Cells are then seeded in two 75 cm2 
flasks per vial of cells.  
 
Name description source ATCC # Ref. 
Caov-3  
Epithelial ovarian papillary 
adenocarcinoma 
human HTB-75 (Karlan & Lagasse, 1994) 
TOV-21G 
Epithelial ovarian poorly 
differentiated primary 
malignant adenocarcinoma; 
Stage IIIC 
human CRL-11730 (Provencher et al., 1993) 
Table 1. Ovarian cancer cell lines used in this work.  
3.1.2 Sub-culturing or passage 
The media is removed and collected for supernatant. The media is replaced with 0.25% 
trypsin/EDTA, and the flask is placed in an incubator for approximately 3-5 minutes. Once 
cells are detached, the suspension is removed and placed in a 15 ml Falcon tube. The cell 
suspension is spun at 200 x g for 1 minute. The trypsin is removed, and the cell pellet is re-
suspended in Complete Medium (amount varies depending on confluence). The suspension 
is seeded into a fresh flask.  
3.1.3 Supernatant collection 
To collect supernatant, the media is removed from the culture flask, placed in 50 ml Falcon 
tube, and spun at 300 x g for 1 minute. The supernatant is removed and placed in a fresh 50 
ml falcon tube. The tubes are then frozen at -80°C.  
3.2 Protein biomarker screening  
Detection of the proteins fibronectin and ApoA-1 are performed in a variety of sample 
backgrounds, including a reagent diluent (containing bovine serum albumin, BSA), human 
serum, cell media, and cell culture supernatant. Figure 7 illustrates the spectral resonance 
peak shifts due to the binding of the ovarian cancer biomarker fibronectin in various 
concentrations. Fibronectin is a high-molecular weight (~440 kDa) extracellular matrix 
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glycoprotein that is known to be produced by some ovarian cancer cell lines. To provide 
selectivity to fibronectin, anti-fibronectin monoclonal antibodies are immobilized on the 
sensor surface using commercial silane surface chemistries and cross-linking agents. Known 
standard concentrations of the target analyte fibronectin are diluted in a reagent diluent 
solution in phosphate buffered saline (PBS, pH 7.4). This reagent provides a BSA blocking 
agent to minimize nonspecific binding during the reaction. Both TE and TM polarization 
resonances are tracked for each concentration. Neat reagent diluent is used as a reference 
blank and subtracted from the data in Fig. 7. Binding is monitored for 1 hour at 37°C. At the 
end of the binding, any loose or unbound fibronectin is rinsed away in PBS, and a post-
binding measurement is taken. Final data is shown using the relative peak shifts recorded 
pre- and post-binding in PBS.  Both TE and TM resonances trend similarly, with the TM 
peak having slightly better detection sensitivity. The limit of detection for this assay is ~20 
ng/ml.  
 
 
 
 
 
 
Fig. 7. Resonance peak shift as a function of concentration for fibronectin binding to its 
matched antibody on the sensor surface. Both TE and TM polarization resonances are 
tracked. Results are repeated in quadruplicate and averaged. 
Figure 8 illustrates fibronectin detected in Caov-3 cell culture media and supernatant. The 
TM resonance peak shift for the test sample (unknown) is compared to the standard 
concentration (known) to obtain a measured concentration of 439.1 ng/ml for Caov-3 media 
and 996.7 ng/ml for Caov-3 supernatant. This indicates that the cell line is expressing 
fibronectin under culture conditions. Additional concentration measurements were 
performed for detection of fibronectin in TOV-21G media and cell culture supernatant. 
Summarized results comparing measured concentrations of both Caov-3 and TOV-21G are 
shown in Fig. 9. For TOV-21G (a stage IIIC ovarian cancer cell line), fibronectin levels are 
reduced during cell culture. 
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Fig. 8. Resonance peak shift as a function of concentration for detection of fibronectin. 
Standards are generated in a reagent diluent background. Caov-3 supernatant (green) and 
media (red) sample resonance shifts are compared to the known concentration resonance shifts 
(standard curve in blue) to obtain Fibronectin concentrations. All measurements are repeated 
in quadruplicate and averaged. Some standard deviations are too small to display on chart. 
 
 
Fig. 9. Comparison of the measured fibronectin in cell culture media and expressed 
supernatant for two different ovarian cancer cell lines.  
Detection of the expressed biomarker protein ApoA-1 in the ovarian cancer cell culture 
supernatant was also quantified for cell lines Caov-3 and TOV-21G. ApoA-1 is a protein 
component of high-density lipoprotein in plasma, and it has an approximate molecular weight 
of 28 kDa. In this experiment, anti-ApoA-1 antibodies are immobilized on the sensor surface to 
provide targeted selectivity for detection. Figure 10 illustrates measured TM-resonance shifts 
for standard known concentrations of ApoA-1 in reagent diluent (shown in blue). We also 
measure unknown amounts of ApoA-1 in fresh (unused) cell culture media and in ovarian 
cancer cell supernatant. The known standards are used to generate a linear calibration curve 
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for the range from 32 ng/ml to 125 ng/ml (with an R2 value of 0.989). Based on this linear fit, 
the fresh cell culture media is found to contain ~59 ng/ml ApoA-1 while the cell culture 
supernatant contains ~89 ng/ml. Binding is monitored for 1 hour at 37°C.  
 
 
Fig. 10. Resonance peak shifts measured for detection of apolipoprotein A-1. Known 
standards are measured (shown in blue) to obtain a calibration curve that is used to quantify 
the unknown samples (shown in red and green). Samples are run in quadruplicate and 
averaged, with major outliers removed. Standard deviation is negligible (shown on plot). 
Figure 11 illustrates detection of the biomarker ApoA-1 in culture media and supernatant 
for the Caov-3 and TOV-21G cell lines. The TM resonance peak shift for the test sample 
(unknown) is compared to the standard concentration (shown in Fig. 10) to obtain a 
measured concentration for each sample. Summarized results comparing measured 
concentrations of both cell media and culture supernatant are shown in Fig. 11. For the 
TOV-21G cell line, ApoA-1 is increased (or expressed) in the measured supernatant. In the 
Caov-3, the measured amount in the supernatant is reduced during culture. Tests are run in 
quadruplicate and averaged. 
 
 
Fig. 11. Comparison of the measured ApoA-1 in cell culture media and expressed supernatant 
for two different ovarian cancer cell lines. Standard deviation is negligible (shown on plot). 
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3.3 Nonspecific binding 
To investigate the amount of nonspecific binding that might occur during the 
media/supernatant and serum experiments, we prepare a negative reference well using a 
blocked silanized well (no antibodies attached); it is compared to wells containing specific 
antibodies for ApoA-1 and fibronectin. The capture antibodies for ApoA-1 and fibronectin 
are monoclonal mouse antibodies that are chemically attached to the sensor surface using 
a silane-based crosslinking agent. After antibody attachment, the unbound sites are 
blocked with a blocking buffer (BSA). In Figure 12, a cell culture media sample (having 
ApoA-1 naturally present) is incubated (1 hour) on sensor wells containing antibodies 
specific for ApoA-1 and wells that have no antibodies present. Figure 12 illustrates the 
minimal shift results from the negative reference well (no antibodies) as compared to the 
well containing the specific antibodies (large shift). We also investigate the use of human 
serum as a sample background in the detection of fibronectin. Figure 13 illustrates the 
resonance peak shift results from a serum sample (naturally containing fibronectin) after 
incubation (1 hour) on a negative reference well (no antibodies) compared to the specific 
antibody coated region. Both of these results are based on the difference of initial and 
final PBS baseline readings.  
 
 
Fig. 12. Comparison of the TM resonant peak shift due to binding of the biomarker ApoA-1 
(in a cell media background) to the ApoA-1 antibodies on the sensors surface versus 
nonspecific binding on the sensor elements not coated with antibodies.  
Since the cell media and supernatant samples are made up of complex matrices, we used a 
spike and recovery method (Thermo, 2007) for each biomarker protein assay to determine 
whether the protein detection is affected by a difference between the diluent used to 
prepare the standard curve and the cell media sample matrix. In spike and recovery 
experiments, a known amount of protein standard is added to the sample matrix 
(corresponding growth media for each cell line) and compared to a standard curve 
measured in diluent. The two sets of total resonance peak shift measurements are 
compared. Table 2 shows results for spike and recovery experiments performed for 
fibronectin in both Caov-3 and TOV-21G cell culture media. Measurements are based on 
the difference of initial and final baseline readings with pure reagent diluent or pure 
media used as negative controls and subtracted from the data. In both cases, the detected 
amount was within ~10% of the target. 
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Fig. 13. Comparison of the TM resonant peak shift due to the binding of fibronectin (in 
human serum) to the fibronectin antibodies on the sensors surface versus the nonspecific 
binding on the sensor elements not coated with antibodies. Tests are run in quadruplicate 
and averaged. 
 
Medium 
Spike 
(ng/ml) 
Standard Resonance 
Peak Shift (nm) 
Spiked Resonance 
Peak Shift (nm) 
Recovery 
% 
Caov-3 500 0.129 0.135 104.7 
TOV-21G 500 0.129 0.116 89.9 
Table 2. Fibronectin Spike and Recovery.  
4. Dual-peak analysis 
As shown in Fig. 1, there are separate resonance peaks for each polarization (TE and TM) 
that shift in response to a given measurement. By backfitting this dual-peak response into 
our rigorous electromagnetic coupled wave analysis codes (Gaylord & Moharam, 1985), we 
can determine two unknowns: surface changes due to analyte binding and bulk refractive-
index changes that occur due to sample background variations. First, we calculate and map 
the predicted TE and TM resonance peak shifts over a relevant range of added biolayer 
thicknesses (0 to 50 nm) and background index variations (n=1.33 to n=1.5). A simple matrix 
is applied to match the corresponding detection layer and background index when the two 
resonance peak shifts are known. This data is fitted assuming a known biolayer refractive 
index, with unknown values to be determined for the biolayer thicknesses and background 
index. To illustrate the utility of this approach, we use the ionic polymer poly (allylamine 
hydrochloride) to study binding interactions that involve biolayer adhesion and associated 
thickness change at the sensor surface (Magnusson et al., 2011). Two resonance peaks are 
tracked as the ionic polymer attaches a monolayer of material as shown in Fig. 14. After the 
polymer saturates, the measurement is paused and the sensor is washed to remove any 
unbound polymer. A post-binding measurement is made in DI water. The results in Fig. 15 
show that the binding of the polymer layer to the sensor surface contributes most to the 
measured response. The fitted background drift is partially attributed to thermal changes in 
the sample during the measurement and imperfect model assumptions (such as polymer 
layer index). Improvements to the backfit model will further distinguish these contributions. 
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Fig. 14. Resonance peak shifts as a function of time for binding ionic polymer to the sensor 
surface. Both TE and TM resonances are monitored. This medium has a molecular weight of 
56,000 kDa.  
 
                                      
Fig. 15. Results of backfitting to a simple model, thereby differentiating contributions from 
biolayer adhesion and background changes.  
5. Conclusions 
A novel diagnostic system to detect biomarkers relevant for diagnosis of ovarian cancer has 
been developed. This label-free sensor system can accurately and rapidly detect an array of 
protein markers with minimal sample processing requirements. Sensor performance was 
characterized for the biomarker proteins fibronectin and apoliprotein A-1 with limits of 
detection measured to be ~20 ng/ml in backgrounds of cell culture media and human 
serum. An in vitro cell culture model was used with established ovarian cancer cell lines to 
provide relevant samples for this work. Nonspecific binding effects were investigated for 
operation in serum backgrounds with minimal impact. Additionally, due to inherent 
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polarization diversity, these sensors employ multiple resonance peaks that are used to 
increase detection accuracy by providing multiple data points for each test. Work is ongoing 
to integrate this system into a portable detection unit that can be used in a point-of-care 
setting. Future work will include clinical sample validation and an expanded array of 
relevant biomarkers that can be tested in a single sample. This will provide a highly accurate 
rapid screening tool for early detection of ovarian cancer.  
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